Low Libido in Women: Every Prescription Option, Compared
Two FDA-approved medications exist for hypoactive sexual desire disorder, the daily pill flibanserin (Addyi®) and the as-needed injection bremelanotide (Vyleesi®), alongside off-label testosterone, compounded topicals, and the non-drug work that is sometimes the actual answer. The map, the trade-offs, and the questions that sort them.
Reviewed by board-certified physicians · Published 2026-08-28 · Updated 2026-08-28 · 10 min read
Key facts
The two FDA-approved HSDD medications work oppositely in rhythm: Addyi® (flibanserin) is a nightly pill; Vyleesi® (bremelanotide) is an as-needed injection.
In late 2025 the FDA expanded flibanserin's approval beyond premenopausal women to include menopausal women up to 65, a meaningful shift in who has an on-label option.
Flibanserin carries an alcohol interaction warning centered on low blood pressure and fainting; current labeling manages timing rather than demanding lifetime abstinence.
No testosterone product is FDA-approved for women; off-label use in postmenopausal women with HSDD has meaningful specialty-society support at physiologic doses.
Low desire is frequently secondary to something else: medications, thyroid, depression, relationship context. The differential is the treatment decision.
Why is the diagnosis the real starting point?
Hypoactive sexual desire disorder is defined by persistent low desire causing distress, not better explained by something else, and that final clause does the clinical work. Antidepressants, hormonal contraceptives, thyroid disease, iron deficiency, depression itself, sleep deprivation, pain with sex, and relationship dynamics all suppress desire, and each has its own fix that a desire drug would merely paper over. A physician working the differential is not gatekeeping; they are aiming.
Two screening facts worth volunteering at evaluation: every medication and supplement you take, and whether desire is low everywhere or specifically in one context, because generalized and situational patterns point different directions. The arousal-versus-desire distinction matters here too, covered in our arousal cream evidence review: products addressing physical response do not treat absent interest, and vice versa.
What is Addyi®, and what does daily dosing involve?
Flibanserin is a nightly oral medication acting on serotonin and dopamine receptor systems, originally developed as an antidepressant, approved for acquired generalized HSDD. Taken every night at bedtime regardless of intimacy plans, it is a background treatment whose effect, in trials, appeared over weeks: modest average improvements versus placebo in desire measures and satisfying events, in the studied populations. Individual results vary and are not typical.
Its famous companion rule involves alcohol: co-ingestion can produce meaningful blood-pressure drops and fainting, and the label's approach has evolved into timing management, separating drinking from the nightly dose, rather than the original absolute prohibition. Bedtime dosing itself exists because sleepiness and dizziness are its common effects. The 2025 expansion of its approval to include menopausal women up to 65 moved a large population from off-label to on-label overnight, and is recent enough that many clinicians' mental maps have not caught up.
How does Vyleesi® compare as the as-needed alternative?
Bremelanotide inverts every practical property: no daily commitment, a subcutaneous autoinjector used before anticipated intimacy, ceilings of one dose per day and eight per month, nausea as the signature early side effect, and transient blood-pressure rises that exclude uncontrolled hypertension. Its trials showed significant average improvements in desire and distress measures versus placebo in premenopausal women with acquired generalized HSDD; the full picture, including the compounded PT-141 landscape, lives in our dedicated guide.
The choice between the two approved drugs is rarely about potency rankings and almost always about rhythm and profile: a nightly pill with an alcohol-timing rule and gradual onset, versus an event-based injection with a nausea adjustment period and monthly ceilings. Life pattern, drinking habits, needle comfort, and blood pressure decide more than any head-to-head number, and no completed head-to-head trial exists to consult anyway.
3/mo CHROMA23+ Membership, medication priced separately, every cost shown first.
Awkwardly but genuinely. No testosterone product is FDA-approved for women in the US, and the evidence base is strongest in one specific population: postmenopausal women with HSDD, where a global consensus statement endorsed by the major specialty societies supports a trial of physiologic-dose testosterone, typically achieved with fractions of male-labeled products or compounded preparations, with monitoring of levels and effects. Outside that population, evidence thins quickly, and supraphysiologic dosing, pellets and aggressive protocols included, is where the field's legitimate concern concentrates.
For a woman whose picture fits, this is a physician-managed protocol with lab work, explicit dosing targets, and periodic reassessment. HRT context matters too: estrogen status, menopausal symptoms, and vaginal health all interact with the desire conversation, and sometimes addressing those is the higher-yield first move.
What about the compounded topicals and everything else?
The compounded shelf, arousal creams built on sildenafil-class pharmacology and compounded PT-141 formats, occupies the space between the approved products: patient-specific prescriptions, no product trials of their own, roles defined by physician judgment, all covered in detail in the linked guides. Beyond prescriptions entirely sit the interventions with quietly strong evidence for the right cases: adjusting a desire-suppressing antidepressant, treating the thyroid, sex therapy and couples work where the pattern is situational, and pelvic health treatment where pain is in the loop.
The realistic promise of this whole landscape is not a switch to flip but a set of levers, each matched to a specific version of the problem. The evaluation exists to find your version; at CHROMA23®, that conversation starts with a free assessment reviewed by a board-certified physician, with every cost shown before anything is prescribed.
Frequently asked questions
Can I drink at all on Addyi®?
Current labeling manages timing rather than banning alcohol outright: drinking is separated from the nightly dose by a specified window rather than prohibited for life. The specifics belong to your prescription conversation, and pretending the interaction away is the one clearly wrong answer.
Which works better, Addyi® or Vyleesi®?
No completed head-to-head trial compares them, and their trial programs measured overlapping but distinct things in distinct populations. The clinically useful comparison is fit: daily versus as-needed, alcohol patterns, needle comfort, blood pressure, and how each profile lands on your actual life.
Is HRT itself a libido treatment?
Menopausal hormone therapy treats menopausal symptoms, and improving sleep, hot flashes, and vaginal comfort often helps desire indirectly; it is not itself an approved desire treatment. The common clinical sequence in menopause addresses those foundations first, then considers desire-specific options against what remains.
My antidepressant killed my libido. Do I just add one of these drugs on top?
Not as a default. Antidepressant-associated low desire is its own well-described problem with its own moves, dose timing, agent switches where clinically safe, and adjuncts, decided with whoever manages your mental health. Adding a desire drug without that conversation treats the label instead of the cause.
Are there age limits on these medications?
Flibanserin's 2025 expansion covers menopausal women up to 65; bremelanotide's approval is for premenopausal women. Outside labeled populations, use becomes off-label physician judgment, which is legal, common, and exactly the kind of decision that deserves an actual evaluation.
About CHROMA23®
CHROMA23® is a clinical weight loss platform built on prescription protocols: injectables, oral medicine, and the protocols that come next, under one 3 membership. Every prescription decision is made by an independent, board-certified physician licensed in the patient's state, and every medication is dispensed by a state-licensed pharmacy. The assessment is free. The membership is 3. The medicine is real. The physician is real.
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Always consult a board-certified physician about your individual situation. Figures from named clinical trials describe study populations; individual results vary and are not typical.